Evaluation of a syndromic panel polymerase chain reaction (spPCR) assay for the diagnosis of device associated bone and joint infections (BJI)

Laura Berneking; Michaela Haas; Lisa Frielinghaus; Benjamin Berinson; Marc Lütgehetmann; Martin Christner; Martin Aepfelbacher; Ulf Gerlach; Klaus Seide; Anna Both; Holger Rohde

doi:10.1016/j.ijid.2022.01.013

Evaluation of a syndromic panel polymerase chain reaction (spPCR) assay for the diagnosis of device associated bone and joint infections (BJI)

Standard

Evaluation of a syndromic panel polymerase chain reaction (spPCR) assay for the diagnosis of device associated bone and joint infections (BJI). / Berneking, Laura; Haas, Michaela; Frielinghaus, Lisa; Berinson, Benjamin ; Lütgehetmann, Marc ; Christner, Martin ; Aepfelbacher, Martin; Gerlach, Ulf; Seide, Klaus; Both, Anna ; Rohde, Holger.

In: INT J INFECT DIS, Vol. 116, 03.2022, p. 283-288.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Berneking, L, Haas, M, Frielinghaus, L, Berinson, B , Lütgehetmann, M , Christner, M , Aepfelbacher, M, Gerlach, U, Seide, K, Both, A & Rohde, H 2022, 'Evaluation of a syndromic panel polymerase chain reaction (spPCR) assay for the diagnosis of device associated bone and joint infections (BJI)', INT J INFECT DIS, vol. 116, pp. 283-288. https://doi.org/10.1016/j.ijid.2022.01.013

APA

Berneking, L., Haas, M., Frielinghaus, L., Berinson, B., Lütgehetmann, M., Christner, M., Aepfelbacher, M., Gerlach, U., Seide, K., Both, A., & Rohde, H. (2022). Evaluation of a syndromic panel polymerase chain reaction (spPCR) assay for the diagnosis of device associated bone and joint infections (BJI). INT J INFECT DIS, 116, 283-288. https://doi.org/10.1016/j.ijid.2022.01.013

Vancouver

Berneking L, Haas M, Frielinghaus L, Berinson B , Lütgehetmann M , Christner M et al. Evaluation of a syndromic panel polymerase chain reaction (spPCR) assay for the diagnosis of device associated bone and joint infections (BJI). INT J INFECT DIS. 2022 Mar;116:283-288. https://doi.org/10.1016/j.ijid.2022.01.013

Bibtex

@article{ac2e91b0438b48379ee565a2d567506e,

title = "Evaluation of a syndromic panel polymerase chain reaction (spPCR) assay for the diagnosis of device associated bone and joint infections (BJI)",

abstract = "OBJECTIVE: Pathogen detection is crucial for diagnosis and targeted therapy in implant-associated bone and joint infections (BJI). Culture-based microbiology regularly fails to identify causative pathogens. This study evaluated the diagnostic accuracy and clinical usefulness of a syndromic panel polymerase chain reaction (spPCR) assay targeting common BJI pathogens in tissue specimens from patients with implant-associated BJI.METHODS: Results obtained by spPCR assay and a 16S rDNA PCR were compared with results obtained from a standard of care (SOC) culture-based diagnostics, serving as a gold standard. In total, 126 specimens obtained from 73 patients were analyzed.RESULTS: The spPCR assay correctly identified 33/40 culture-positive samples (82.5 %) and was positive in 9/86 (10.5 %) culture-negative samples, resulting in an overall sensitivity of 84.6 % (95% confidence interval [CI] 68.79-93.59%) and specificity of 89.35% (95% CI 80.6-94.81%). The spPCR was more sensitive compared with the 16S rDNA PCR (37.5%). The spPCR identified pathogens in 7/51 (13.7%) SOC-negative patients. Re-evaluation of spPCR results in clinical context suggested their clinical significance.CONCLUSION: An spPCR assay targeting common pathogens causing implant-associated BJI may help to identify causative agents in culture-negative cases. As false-negative results are possible, spPCR assays appear as an add-on approach for pathogen detection in implant-associated BJI.",

author = "Laura Berneking and Michaela Haas and Lisa Frielinghaus and Benjamin Berinson and Marc L{\"u}tgehetmann and Martin Christner and Martin Aepfelbacher and Ulf Gerlach and Klaus Seide and Anna Both and Holger Rohde",

note = "Copyright {\textcopyright} 2022. Published by Elsevier Ltd.",

year = "2022",

month = mar,

doi = "10.1016/j.ijid.2022.01.013",

language = "English",

volume = "116",

pages = "283--288",

journal = "INT J INFECT DIS",

issn = "1201-9712",

publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Evaluation of a syndromic panel polymerase chain reaction (spPCR) assay for the diagnosis of device associated bone and joint infections (BJI)

AU - Berneking, Laura

AU - Haas, Michaela

AU - Frielinghaus, Lisa

AU - Berinson, Benjamin

AU - Lütgehetmann, Marc

AU - Christner, Martin

AU - Aepfelbacher, Martin

AU - Gerlach, Ulf

AU - Seide, Klaus

AU - Both, Anna

AU - Rohde, Holger

PY - 2022/3

Y1 - 2022/3

N2 - OBJECTIVE: Pathogen detection is crucial for diagnosis and targeted therapy in implant-associated bone and joint infections (BJI). Culture-based microbiology regularly fails to identify causative pathogens. This study evaluated the diagnostic accuracy and clinical usefulness of a syndromic panel polymerase chain reaction (spPCR) assay targeting common BJI pathogens in tissue specimens from patients with implant-associated BJI.METHODS: Results obtained by spPCR assay and a 16S rDNA PCR were compared with results obtained from a standard of care (SOC) culture-based diagnostics, serving as a gold standard. In total, 126 specimens obtained from 73 patients were analyzed.RESULTS: The spPCR assay correctly identified 33/40 culture-positive samples (82.5 %) and was positive in 9/86 (10.5 %) culture-negative samples, resulting in an overall sensitivity of 84.6 % (95% confidence interval [CI] 68.79-93.59%) and specificity of 89.35% (95% CI 80.6-94.81%). The spPCR was more sensitive compared with the 16S rDNA PCR (37.5%). The spPCR identified pathogens in 7/51 (13.7%) SOC-negative patients. Re-evaluation of spPCR results in clinical context suggested their clinical significance.CONCLUSION: An spPCR assay targeting common pathogens causing implant-associated BJI may help to identify causative agents in culture-negative cases. As false-negative results are possible, spPCR assays appear as an add-on approach for pathogen detection in implant-associated BJI.

AB - OBJECTIVE: Pathogen detection is crucial for diagnosis and targeted therapy in implant-associated bone and joint infections (BJI). Culture-based microbiology regularly fails to identify causative pathogens. This study evaluated the diagnostic accuracy and clinical usefulness of a syndromic panel polymerase chain reaction (spPCR) assay targeting common BJI pathogens in tissue specimens from patients with implant-associated BJI.METHODS: Results obtained by spPCR assay and a 16S rDNA PCR were compared with results obtained from a standard of care (SOC) culture-based diagnostics, serving as a gold standard. In total, 126 specimens obtained from 73 patients were analyzed.RESULTS: The spPCR assay correctly identified 33/40 culture-positive samples (82.5 %) and was positive in 9/86 (10.5 %) culture-negative samples, resulting in an overall sensitivity of 84.6 % (95% confidence interval [CI] 68.79-93.59%) and specificity of 89.35% (95% CI 80.6-94.81%). The spPCR was more sensitive compared with the 16S rDNA PCR (37.5%). The spPCR identified pathogens in 7/51 (13.7%) SOC-negative patients. Re-evaluation of spPCR results in clinical context suggested their clinical significance.CONCLUSION: An spPCR assay targeting common pathogens causing implant-associated BJI may help to identify causative agents in culture-negative cases. As false-negative results are possible, spPCR assays appear as an add-on approach for pathogen detection in implant-associated BJI.

U2 - 10.1016/j.ijid.2022.01.013

DO - 10.1016/j.ijid.2022.01.013

M3 - SCORING: Journal article

C2 - 35031396

VL - 116

SP - 283

EP - 288

JO - INT J INFECT DIS

JF - INT J INFECT DIS

SN - 1201-9712

ER -